OOIR: Observatory of International Research

Papers

(The median citation count of Journal of Pharmacokinetics and Pharmacodynamics is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Thanks to our reviewers 2021!	90
Reliability of in vitro data for the mechanistic prediction of brain extracellular fluid pharmacokinetics of P-glycoprotein substrates in vivo; are we scaling correctly?	40
No QT interval prolongation effect of sepiapterin: a concentration-QTc analysis of pooled data from phase 1 and phase 3 studies in healthy volunteers and patients with phenylketonuria	38
The Finite Absorption Time (FAT) concept en route to PBPK modeling and pharmacometrics	36
Authors’ response to letter to editor	35
A next generation mathematical model for the in vitro to clinical translation of T-cell engagers	29
Population pharmacokinetic and pharmacokinetic-pharmacodynamic modeling of bempedoic acid and low-density lipoprotein cholesterol in healthy subjects and patients with dyslipidemia	28
Translational physiologically-based pharmacokinetic model for ocular disposition of monoclonal antibodies	21
Development of PBPK model for intra-articular injection in human: methotrexate solution and rheumatoid arthritis case study	21
Correction to: R-praziquantel integrated population pharmacokinetics in preschool- and school-aged African children infected with Schistosoma mansoni and S. haematobium and Lao adults infected with Op	18
PBPK model for antibody disposition in mouse brain: validation using large-pore microdialysis data	14
Variability and uncertainty: interpretation and usage of pharmacometric simulations and intervals	12
Learning pharmacometric covariate model structures with symbolic regression networks	12
Concentration-QTc analysis with two or more correlated baselines	12
From data to QSP models: a pipeline for using Boolean networks for hypothesis inference and dynamic model building	12
Population pharmacokinetic and pharmacodynamic model of propofol externally validated in Korean elderly subjects	11
Time Scale Calculus: a new approach to multi-dose pharmacokinetic modeling	10
A quantitative systems pharmacology model of plasma kallikrein-kinin system dysregulation in hereditary angioedema	10
Application of different approaches to generate virtual patient populations for the quantitative systems pharmacology model of erythropoiesis	9
Mechanistic incorporation of FcRn binding in plasma and endosomes in a whole body PBPK model for large molecules	9
Correction to: Characterization of exposure–Clinical Dementia Rating–Sum of Boxes relationship in subjects with early Alzheimer’s disease from the aducanumab Phase 3 trials	9
Advancing cancer drug development with mechanistic mathematical modeling: bridging the gap between theory and practice	8
A quantitative systems pharmacology model for simulating OFF-Time in augmentation trials for Parkinson’s disease: application to preladenant	8
Likelihood comparisons in bounded outcome score analysis must be internally consistent	8
Correction: External control arms for rare diseases: building a body of supporting evidence	8

Population pharmacokinetic/pharmacodynamic modeling of nifekalant injection with varies dosing plan in Chinese volunteers: a randomized, blind, placebo-controlled study	7
Understanding virtual patients efficiently and rigorously by combining machine learning with dynamical modelling	7
Individualized optimization of colistin loading doses	7
Convolution-based approach for modeling the paliperidone extended release and Long-Acting Injectable (LAI) PK of once-, and three-monthly products administration and for optimizing the development of	7
Achieving big with small: quantitative clinical pharmacology tools for drug development in pediatric rare diseases	7
Systemic exposure following intravitreal administration of therapeutic agents: an integrated pharmacokinetic approach. 2. THR-687	7
A quantitative modeling framework to understand the physiology of the hypothalamic-pituitary-adrenal axis and interaction with cortisol replacement therapy	7
Should patients skip late doses of medication? A pharmacokinetic perspective	7
Rare oncology therapeutics: review of clinical pharmacology package of drug approvals (2019–2023) by US FDA, best practices and recommendations	7
Visual predictive check of longitudinal models and dropout	7
Analysis of cellular kinetic models suggest that physiologically based model parameters may be inherently, practically unidentifiable	6
A two-stages global sensitivity analysis by using the δ sensitivity index in presence of correlated inputs: application on a tumor growth inhibition model based on the dynamic energy budget theory	6
Joint longitudinal model-based meta-analysis of FEV1 and exacerbation rate in randomized COPD trials	6
Delay differential equations based models in NONMEM	6
Clinical validation of translational antibody PBPK model using tissue distribution data generated with 89Zr-immuno-PET imaging	6
Evaluation of covariate effects using variance-based global sensitivity analysis in pharmacometrics	6
Special issue: chronopharmacometrics	6
Implementation of non-linear mixed effects models defined by fractional differential equations	6
Semi-mechanistic modeling of resistance development to β-lactam and β-lactamase-inhibitor combinations	5
Generation and application of avatars in pharmacometric modelling	5
Physiologically-based pharmacokinetic model for pulmonary disposition of protein therapeutics in humans	5
Correction: Model-based comparison of subcutaneous versus sublingual apomorphine administration in the treatment of motor fluctuations in Parkinson’s disease	5
Towards a platform quantitative systems pharmacology (QSP) model for preclinical to clinical translation of antibody drug conjugates (ADCs)	5
Characterization of exposure–Clinical Dementia Rating–Sum of Boxes relationship in subjects with early Alzheimer’s disease from the aducanumab Phase 3 trials	5
Predicting efficacy assessment of combined treatment of radiotherapy and nivolumab for NSCLC patients through virtual clinical trials using QSP modeling	5
A population pharmacokinetics model of balovaptan to support dose selection in adult and pediatric populations	5
A PopPBPK-RL approach for precision dosing of benazepril in renal impaired patients	5
Mixed effect estimation in deep compartment models: Variational methods outperform first-order approximations	5
Recommendations for a standardized publication protocol for a QSP model	4
Virtual clinical trials via a QSP immuno-oncology model to simulate the response to a conditionally activated PD-L1 targeting antibody in NSCLC	4
Sampling from covariate distribution may not always be necessary in PK/PD simulations: illustrative examples with antibiotics	4
A review of the physiological effects of microgravity and innovative formulation for space travelers	4
Wide size dispersion and use of body composition and maturation improves the reliability of allometric exponent estimates	4
Novel endpoints based on tumor size ratio to support early clinical decision-making in oncology drug-development	4
Model-informed approach to estimate treatment effect in placebo-controlled clinical trials using an artificial intelligence-based propensity weighting methodology to account for non-specific responses	4
An integrated modelling approach for targeted degradation: insights on optimization, data requirements and PKPD predictions from semi- or fully-mechanistic models and exact steady state solutions	4
Translational population target binding model for the anti-FcRn fragment antibody efgartigimod	4
The impact of misspecified covariate models on inclusion and omission bias when using fixed effects and full random effects models	4
Population pharmacodynamic modeling of intramuscular and oral dexamethasone and betamethasone effects on six biomarkers with circadian complexities in Indian women	3
Comparison of the power and type 1 error of total score models for drug effect detection in clinical trials	3
Semi-empirical anticoagulation model (SAM): INR monitoring during Warfarin therapy	3
A physiologically-based pharmacokinetic model to describe antisense oligonucleotide distribution after intrathecal administration	3
Lumbar cerebrospinal fluid-to-brain extracellular fluid surrogacy is context-specific: insights from LeiCNS-PK3.0 simulations	3
A quantitative systems pharmacology model of plasma potassium regulation by the kidney and aldosterone	3
Correction to: Modeling the acute effects of exercise on glucose dynamics in healthy nondiabetic subjects	3
Employing zero-inflated beta distribution in an exposure-response analysis of TYK2/JAK1 inhibitor brepocitinib in patients with plaque psoriasis	3
Empirical bayes approach for dynamic bayesian borrowing for clinical trials in rare diseases	3
Changes in Associate Editors at the Journal of Pharmacokinetics and Pharmacodynamics	3
Physiologically-based pharmacokinetic modeling to predict drug-drug interaction of enzalutamide with combined P-gp and CYP3A substrates	3
Impact of covariate model building methods on their clinical relevance evaluation in population pharmacokinetic analyses: comparison of the full model, stepwise covariate model (SCM) and SCM+ approach	3

Translational two-pore PBPK model to characterize whole-body disposition of different-size endogenous and exogenous proteins	3
Operational characteristics of full random effects modelling (‘frem’) compared to stepwise covariate modelling (‘scm’)	3
Current practices for QSP model assessment: an IQ consortium survey	3
Pharmacodynamic model of slow reversible binding and its applications in pharmacokinetic/pharmacodynamic modeling: review and tutorial	3
Correction: Oral docetaxel plus encequidar – a pharmacokinetic model and evaluation against IV docetaxel	3
Experimental and computational assessment of the synergistic pharmacodynamic drug–drug interactions of a triple combination therapy in refractory HER2-positive breast cancer cells	2
Physiologically-based pharmacokinetic model for 2,4-dinitrophenol	2
Quantifying natural amyloid plaque accumulation in the continuum of Alzheimer’s disease using ADNI	2
Imputation of missing clock times – application to procalcitonin concentration time course after birth	2
Information-theoretic evaluation of covariate distributions models	2
Comparison of monoclonal antibody disposition predictions using different physiologically based pharmacokinetic modelling platforms	2
Note on importance of correct stoichiometric assumptions for modeling of monoclonal antibodies	2
ChatGPT and Gemini large language models for pharmacometrics with NONMEM: comment	2
Use of population PK/PD approach to model the thrombin generation assay: assessment in haemophilia A plasma samples spiked by a TFPI antibody	2
Application of machine learning based methods in exposure–response analysis	2
Training the next generation of pharmacometric modelers: a multisector perspective	2
Thoughts on plagiarism and the case against Claudine Gay	2
Prospective approaches to gene therapy computational modeling – spotlight on viral gene therapy	2
Generative models for synthetic data generation: application to pharmacokinetic/pharmacodynamic data	2
Oral docetaxel plus encequidar – A pharmacokinetic model and evaluation against IV docetaxel	2
Explaining in-vitro to in-vivo efficacy correlations in oncology pre-clinical development via a semi-mechanistic mathematical model	2
Population pharmacokinetics and pharmacodynamics of efmarodocokin alfa (IL-22Fc)	2
Correction to: Abstracts for the Ninth American Conference on Pharmacometrics (ACoP9)	2
Comparison of sequential and joint nonlinear mixed effects modeling of tumor kinetics and survival following Durvalumab treatment in patients with metastatic urothelial carcinoma	2
An exploratory analysis of the performance of methylphenidate regimens based on a PKPD model of dopamine and norepinephrine transporter occupancy	1
Semi-mechanistic population pharmacokinetic modeling of DZIF-10c, a neutralizing antibody against SARS-Cov-2: predicting systemic and lung exposure following inhaled and intravenous administration	1
Computing optimal drug dosing regarding efficacy and safety: the enhanced OptiDose method in NONMEM	1
Pharmacometric model of agalsidase–migalastat interaction in human: a novel mechanistic model of drug-drug interaction between a therapeutic protein and a small molecule	1
QTc interval analysis—an ever-evolving endeavor	1
Development of a genetic algorithm and NONMEM workbench for automating and improving population pharmacokinetic/pharmacodynamic model selection	1
Optimal sample selection applied to information rich, dense data	1
Generative adversarial networks for construction of virtual populations of mechanistic models: simulations to study Omecamtiv Mecarbil action	1
Subgroup identification-based model selection to improve the predictive performance of individualized dosing	1
A series acceleration algorithm for the gamma-Pareto (type I) convolution and related functions of interest for pharmacokinetics	1
Inferring pulmonary exposure based on clinical PK data: accuracy and precision of model-based deconvolution methods	1
Linking categorical models for prediction of pleasantness score using individual predictions of sweetness and creaminess: An advancement of categorical modeling	1
A comprehensive regulatory and industry review of modeling and simulation practices in oncology clinical drug development	1
Challenges, approaches and enablers: effectively triangulating towards dose selection in pediatric rare diseases	1
Computing optimal drug dosing with OptiDose: implementation in NONMEM	1
Pharmacometric estimation methods for aggregate data, including data simulated from other pharmacometric models	1
An industry perspective on current QSP trends in drug development	1
Computational neurosciences and quantitative systems pharmacology: a powerful combination for supporting drug development in neurodegenerative diseases	1
Integrated multiple analytes and semi-mechanistic population pharmacokinetic model of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate	1
Model-based comparison of subcutaneous versus sublingual apomorphine administration in the treatment of motor fluctuations in Parkinson’s disease	1
Optimal control for colistin dosage selection	1
Mechanistic inference of the metabolic rates underlying $$^{13}$$C breath test curves	1
Global sensitivity analysis in physiologically-based pharmacokinetic/pharmacodynamic models of inhaled and opioids anesthetics and its application to generate virtual populations	1
Correction to: Classical structural identifiability methodology applied to low-dimensional dynamic systems in receptor theory	1
A physiologically-based quantitative systems pharmacology model for mechanistic understanding of the response to alogliptin and its application in patients with renal impairment	1
Go beyond the limits of genetic algorithm in daily covariate selection practice	1
Circadian rhythms: influence on physiology, pharmacology, and therapeutic interventions	1
JPKPD October Special Issue - Commentary	1
Population pharmacokinetic model selection assisted by machine learning	1